Skip to main navigation

Our Science
AT-527
COVID-19
About Atea
Investors
Careers
Contact

The tip of a pipette pointing towards droplets suspended in a green solution.

Investor Relations

Publications

Breadcrumb

Investors
News & Events
Publications

Publications

Evaluation of AT-752, a double prodrug of a guanosine nucleotide analog with in vitro and in vivo activity against dengue and other flaviviruses

Source

AAC Accepted Manuscript Posted Online 23 August 2021 Antimicrob Agents Chemother doi:10.1128/AAC.00988-21

Read More

AT-527, a double prodrug of a guanosine nucleotide analog, is a potent inhibitor of SARS-CoV-2 in vitro and a promising oral antiviral for treatment of COVID-19

Source

Published in Antimicrobial Agents and Chemotherapy. 2021. DOI: 10.1128/AAC.02479-20

Read More

Preclinical Evaluation of AT-527, a Novel Guanosine Nucleotide Prodrug with Potent, Pan-genotypic Activity Against Hepatitis C Virus

Source

Published in PLoS ONE. 2020. DOI: e0227104.

Read More

Safety, Pharmacokinetics, and Antiviral Activity of AT-527, a Novel Purine Nucleotide Prodrug, in Hepatitis C Virus-Infected Subjects with or without Cirrhosis

Source

Published in Antimicrobial Agents & Chemotherapy. 2019. Volume 63, Issue 12. DOI: 10.1128/AAC.01201-19.

Read More

Pagination

First page
Previous page
Page 1
Current page 2

Atea is a clinical-stage biopharmaceutical company working to address unmet medical needs through novel antiviral treatment.

Atea Pharmaceuticals, Inc.
225 Franklin Street
Suite 2100
Boston, MA 02110
(857) 284-8891

Copyright © 2023 By Atea Pharmaceuticals, Inc. All Rights Reserved. Privacy Policy | Terms of Use